AAT-008

• Description:

  AAT-008 is a potent, selective, and orally active prostaglandin EP4 receptor antagonist with Kis of 0.97 and 6.1 nM for recombinant human EP4 and recombinant rat EP4, respectively. AAT-008 exerts tumor growth delay in mice bearing CT26WT colon tumors when combined with radiotherapy. AAT-008 can be used for the study of acute and chronic inflammatory pain and cancer [1][2].

• UNSPSC:

  12352005

• Target:

  Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/aat-008.html

• Concentration:

  10mM

• Purity:

  98.55

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C (O) C1=CC=C ([C@@H] (NC (C2=CC (Cl) =CN=C2OC3=CC=CC (F) =C3) =O) C) C=C1

• Molecular Formula:

  C21H16ClFN2O4

• Molecular Weight:

  414.81

• References & Citations:

  [1]Okumura Y, et al. Discovery of AAT-008, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Bioorg Med Chem Lett. 2017;27 (5) :1186-1192. |[2]Manabe Y, et al. Biological effects of prostaglandin E2-EP4 antagonist (AAT-008) in murine colon cancer in vivo: enhancement of immune response to radiotherapy and potential as a radiosensitizer. Transl Cancer Res. 2023 Feb 28;12 (2) :351-358.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  EP

• CAS Number:

  847727-81-5